Bilastine

Generic Name
Bilastine
Brand Names
Blexten
Drug Type
Small Molecule
Chemical Formula
C28H37N3O3
CAS Number
202189-78-4
Unique Ingredient Identifier
PA1123N395
Background

Bilastine is a novel new-generation antihistamine that is highly selective for the H1 histamine receptor, has a rapid onset and prolonged duration of action.

Indication

For symptomatic relief of nasal and non-nasal symptoms of seasonal rhinitis in patients 12 years of age and older and for symptomatic relief in chronic spontaneous urticaria in patients 18 years of age and older .

Associated Conditions
Chronic Spontaneous Urticaria, Seasonal Allergic Rhinitis
Associated Therapies
-
Clinical Trials
Related News

Study to Assess the Safety, Tolerability and Efficacy of Bilastine Ophthalmic Solution 0.6% in Children

Phase 3
Completed
Conditions
Allergic Conjunctivitis
Interventions
Drug: Placebo
Drug: Bilastine
First Posted Date
2021-03-23
Last Posted Date
2023-03-16
Lead Sponsor
Faes Farma, S.A.
Target Recruit Count
59
Registration Number
NCT04810390
Locations
🇪🇸

Instituto Oftálmologico Quironsalud A Coruña, A Coruña, Spain

🇪🇸

Hospital Universitari German Trias i Pujol (HGTiP),, Badalona, Spain

🇪🇸

Hospital Universitari Dexeus, Barcelona, Spain

and more 15 locations

Effects of Bilastine on F1 Simulator Driving Performance in Patients Affected by Allergic Rhinitis and/or Urticaria

Phase 4
Completed
Conditions
Urticaria
Allergic Rhinitis
Interventions
Drug: Bilastine
Drug: Placebo
First Posted Date
2015-10-15
Last Posted Date
2017-04-18
Lead Sponsor
Menarini International Operations Luxembourg SA
Target Recruit Count
19
Registration Number
NCT02576041
Locations
🇮🇹

Azienda Ospedaliero-Universitaria Policlinico, Modena, Italy

Quality of Life in Patients With Allergic Rhinitis: Clinical Trial With Bilastine or Loratadine

Phase 4
Completed
Conditions
Allergic Rhinitis
Interventions
Drug: Bilastine
Drug: Loratadine
First Posted Date
2015-07-31
Last Posted Date
2018-05-07
Lead Sponsor
Universidade do Sul de Santa Catarina
Target Recruit Count
73
Registration Number
NCT02513290

Bilastine Updosing in Chronic Spontaneous Urticaria

Phase 3
Completed
Conditions
Chronic Urticaria
Interventions
Drug: Bilastine
Drug: Bilastin
First Posted Date
2014-08-11
Last Posted Date
2016-08-26
Lead Sponsor
Charite University, Berlin, Germany
Target Recruit Count
30
Registration Number
NCT02213367
Locations
🇩🇪

Dpt. of Dermatology and Allergy, Berlin, Germany

Evaluation of the Inhibitory Effect of 5 Anti-Histamines in Urticaria

First Posted Date
2013-09-12
Last Posted Date
2014-02-19
Lead Sponsor
Grupo de Alergología Clínica y Experimental
Target Recruit Count
150
Registration Number
NCT01940393
Locations
🇨🇴

Medellin, Medellin, Antioquia, Colombia

Investigate the Safety/Tolerability and Efficacy of Bilastine 20mg in Korean Patients With Seasonal Allergic Rhinitis

First Posted Date
2011-07-22
Last Posted Date
2014-07-10
Lead Sponsor
Yuhan Corporation
Target Recruit Count
239
Registration Number
NCT01400828
Locations
🇰🇷

Yonsei University college of Medicine, Gangnam Severance Hospital, Seoul, Korea, Republic of

Bilastine Updosing - Characterization of Underlying Mechanisms

Phase 2
Completed
Conditions
Cold Contact Urticaria
Interventions
Drug: Bilastine
First Posted Date
2011-01-06
Last Posted Date
2012-05-31
Lead Sponsor
Charite University, Berlin, Germany
Target Recruit Count
20
Registration Number
NCT01271075
Locations
🇩🇪

Charité-Universitätsmedizin Berlin, Berlin, Germany

Efficacy Study for the Symptomatic Treatment of Perennial Allergic Rhinitis With a 1 Year Safety Extension

First Posted Date
2010-05-21
Last Posted Date
2012-09-26
Lead Sponsor
Faes Farma, S.A.
Target Recruit Count
650
Registration Number
NCT01127620

Oral Bioavailability of Bilastine

Phase 1
Completed
Conditions
Healthy
Interventions
Drug: Bilastine
First Posted Date
2010-05-14
Last Posted Date
2012-09-26
Lead Sponsor
Faes Farma, S.A.
Target Recruit Count
12
Registration Number
NCT01124123
Locations
🇪🇸

Unidad de Investigacion Clinica. Clinica Universidad de Navarra, Pamplona, Navarra, Spain

A Phase III Efficacy Study of the Symptomatic Treatment of Seasonal Allergic Rhinitis With Bilastine

First Posted Date
2010-04-22
Last Posted Date
2012-04-05
Lead Sponsor
Faes Farma, S.A.
Target Recruit Count
720
Registration Number
NCT01108783
© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy